Structure Therapeutics Reports Highly Positive Phase 2b Data for Oral Obesity Drug Aleniglipron, Advancing to Phase 3
GPCR has more than doubled off its 52-week low of $13.22.
Summary
Structure Therapeutics reported highly positive Phase 2b clinical trial results for its oral obesity drug, aleniglipron, showing significant weight loss and a favorable safety profile, paving the way for Phase 3 development.
Key Events · Product Development and Regulatory · GPCR
-
Positive Phase 2b ACCESS II Results
Aleniglipron achieved a placebo-adjusted mean weight loss of up to 16.3% at 44 weeks, demonstrating high efficacy for an oral GLP-1RA.
-
Improved Tolerability and Safety Profile
A lower 2.5 mg starting dose significantly reduced adverse event-related discontinuations, and the drug maintained a compelling safety profile with no drug-induced liver injury.
-
Advancement to Phase 3
The company plans an End-of-Phase 2 meeting with the FDA in Q2 2026 and anticipates initiating the Phase 3 program in the second half of 2026.
-
Sustained Weight Loss Observed
Interim data from the ACCESS Open-Label Extension study showed continued weight loss up to 16.2% at 56 weeks, with no evidence of a plateau.
Analysis · GPCR · Life Sciences
Structure Therapeutics announced compelling topline results from its Phase 2 ACCESS II trial for aleniglipron, an oral GLP-1 receptor agonist for obesity. The drug demonstrated significant placebo-adjusted mean weight loss of up to 16.3% at 44 weeks, positioning it as a potential best-in-class oral GLP-1RA with efficacy comparable to injectable therapies. The data also highlighted an improved tolerability profile with a lower starting dose and a strong safety record, with no evidence of drug-induced liver injury. These robust results provide a strong foundation for advancing aleniglipron into Phase 3 clinical development, with an FDA meeting scheduled for Q2 2026 and Phase 3 initiation anticipated in 2H 2026. This significantly de-risks the company's lead asset and strengthens its competitive position in the lucrative obesity market.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 42.3% of the 496 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GPCR was trading at $59.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.8B. The 52-week trading range was $13.22 to $94.90. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.